MedTrace Logo

Cardiovascular Protective Effect of Spironolactone in Hemodialysis

NCT00277693 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2006-01-16

No results posted yet for this study

Summary

The purpose of the present study is to determine if spironolactone is safe and effective in the treatment of cardiovascular complications in hemodialysis patients.

Conditions

  • Hemodialysis

Interventions

DRUG

Spironolactone (drug)

Sponsors & Collaborators

  • Universidad de los Andes, Chile

    lead OTHER

Principal Investigators

  • Luis F Michea, MD PhD · Faculty of Medicine, University Los Andes

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Chile

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00277693 on ClinicalTrials.gov